Tempus AI (NASDAQ:TEM) Poised for Growth: Analyst Upgrade, Strong Data Services, and Upcoming Earnings

• Analyst firm Cowen & Co. maintained a Buy rating and increased its price target for Tempus AI (NASDAQ:TEM) to $71, signaling strong potential upside.
• The company's data services segment demonstrated robust performance, with revenue growing 40% year-over-year to $87 million in Q1 2026.
• A significant 500% year-over-year increase in Minimal Residual Disease (MRD) testing, bolstered by a partnership with Personalis, is a key growth driver.

Tempus AI (NASDAQ:TEM) is a technology company focused on precision medicine. It operates by collecting and analyzing large amounts of clinical and molecular data. The company aims to become a dominant force in healthcare data, using its insights to help doctors personalize patient treatment and accelerate the development of new drugs.

On July 15, 2026, analyst firm Cowen & Co. maintained its Buy rating for Tempus AI. The firm also increased its price target for the stock to $71 from a previous $68. At the time of this announcement, the stock's price was $58.67, showing potential upside based on the analyst's view.

This positive outlook is supported by strong performance in its data services. As highlighted by Seeking Alpha, Tempus AI's data segment revenue grew 40% year-over-year to $87 million in the first quarter of 2026. The company is on track to potentially generate over $500 million in revenue from this segment in 2026.

A key growth driver is a 500% year-over-year increase in Minimal Residual Disease (MRD) testing. These tests detect small amounts of cancer cells after treatment. A partnership with Personalis on a sensitive, reimbursed test is fueling this growth and helps Tempus AI gather valuable data for its pharmaceutical clients.

Investors are looking ahead to the company's next update. As announced by Business Wire, Tempus AI will report its second-quarter 2026 financial results on July 30, 2026. The stock is currently trading at $58.67, with a market capitalization of approximately $10.24 billion.